FDA approves at-home starter dose for Eisai-Biogen Alzheimer's drug

• The subcutaneous formulation (Leqembi IQLIK) allows at-home administration, while previously patients needed 18 months of IV infusions at clinics before switching to maintenance treatment
• The FDA approval was based on earlier IV trials showing effectiveness in early Alzheimer's patients, with the injectable version demonstrating equivalent amyloid plaque reductions without separate large-scale outcome trials
• Possible side effects at injection sites include redness, swelling, rash, pain, or bruising; the drug targets amyloid beta protein that forms plaques in Alzheimer's patients' brains

Summary

FDA Approves At-Home Starter Dose for Eisai-Biogen Alzheimer's Drug

The U.S. FDA approved an at-home starting dose of Leqembi, the Alzheimer's drug developed by Eisai and Biogen, allowing patients to self-administer or receive subcutaneous injections from caregivers. This marks a significant shift from the previous protocol requiring intravenous infusions at clinics before patients could transition to maintenance treatment after 18 months.

Key Details:

• The approval applies to Leqembi IQLIK, the under-the-skin formulation
• Leqembi targets amyloid beta protein, which forms plaques in Alzheimer's patients' brains
• The drug is authorized for adults with early Alzheimer's disease, including mild cognitive impairment or mild dementia with confirmed amyloid buildup

Market Implications:

BMO Capital Markets analyst Evan Seigerman suggests the at-home subcutaneous approval could boost uptake by improving patient access and differentiating Leqembi from competitor Eli Lilly's Kisunla, which requires IV infusions. This convenience factor may provide a competitive advantage in the Alzheimer's treatment market.

Clinical Basis:

The FDA's decision relied on two earlier trials demonstrating the IV version's effectiveness. The subcutaneous version wasn't tested in separate large trials; instead, approval was based on evidence showing equivalent results and similar amyloid plaque reductions compared to the infused version.

Side Effects:

The injectable version may cause injection-site reactions including redness, swelling, rash, pain, or bruising.

This approval represents a meaningful advancement in Alzheimer's treatment accessibility, potentially expanding the patient population able to receive therapy outside clinical settings.